Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Akorn, Inc. (AKRX) and Hi-Tech Pharmacal Co. (HITK)’s Shares Soared

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of branded and generic drug developer Akorn, Inc. (NASDAQ:AKRX) and branded, generic and over-the-counter drugmaker Hi-Tech Pharmacal Co. (NASDAQ:HITK) soared as much as 15% and 26%, respectively, after Akorn announced a deal to buy rival Hi-Tech Pharmacal Co. (NASDAQ:HITK) for $640 million.

Akorn, Inc.

So what: The deal values Hi-Tech Pharmacal Co. (NASDAQ:HITK) at $43.50/share, or a 24% premium from yesterday’s closing price, and is expected to be earnings accretive immediately for Akorn, Inc. (NASDAQ:AKRX). Once completed, Akorn, Inc. (NASDAQ:AKRX) is set to become the third-largest drug company focused on ophthalmic (i.e., eye-related) treatments, and it would also have an expanded line of cold, allergy, and sinus over-the-counter medications to further diversify its product line. Akorn, Inc. (NASDAQ:AKRX) also sees cost savings hitting $15 million to $20 million annually once the deal is completed. Akorn, Inc. (NASDAQ:AKRX) plans to finance the deal primarily through long-term borrowing.

Now what: It’s rare that you see a purchasing company jump nearly as much as the company it’s buying, but that’s exactly the case today. Clearly, investors are thrilled with this combination, the expected cost synergies, and the expanded product pipeline. Even prior to his deal, I was enamored with Akorn, Inc. (NASDAQ:AKRX) given that it planned to introduce (according to its own press release) 39 branded and generic drugs between 2013 and 2015 with a current market value of $3 billion. That’s the great thing about hybrid drug developers, those that develop generic as well as in-house branded drugs: There’s never a dull moment as the research pipeline is always churning. Even following today’s pop, I would suggest getting Akorn on your Watchlist and doing some digging if you’re looking for a solid biopharmaceutical growth story over the next decade or longer.

The article Why Akorn and Hi-Tech Pharmacal’s Shares Soared originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...